Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.16, read 2026-11-05
Ethical passes the values gate
Price10.93 USD
Fair value11.32
Ethical score70.0/100
Value readFairas of 4 Nov 2026
Our investment reviews on this name
2026-10-21Read Accumulation10.06+8.6% to today ✓Markdown gives way to Accumulation after a 9% slide in 8 weeks
2026-08-26Read Markdown11.08-1.4% to today ✓Markup gives way to Markdown after a 15% slide in 8 weeks
2026-07-02Read Markup12.98-15.8% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Cemex SAB de CV ADR holds its Accumulation at $10.93. Consolidating, no directional conviction, held for 82 days.
As held on the ledger · 2026-11-04
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 82 days
Price at the screen
$10.93
Valuation
85.00 trailing · 11.27 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.81
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
23.42%
Below 33%
Interest-bearing debt is just 23.4% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.04%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
12.41%
Below 49%
Money owed to the company is 12.4% of assets, under the 49% limit.
Pass
Revenue purity
0.30%
Below 5%
Only 0.3% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Cemex SAB de CV clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 23%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when CX's ethical verdict changes
Today CX passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 4 Nov 2026: it trades at roughly a 3% discount to our $11.32 fair value, narrow competitive moat, 12.20% revenue growth.
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. A 3.4% discount to the base estimate.
Where our models see it going: fair-value estimate $11.32, with a range of $9.90 to $13.02, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Cement demand rises and falls with every cycle
Picture a Mexican cement works running flat out one year and idling the next as public works budgets swing. Cemex sits right in that rhythm, selling the concrete that builds roads and homes across emerging markets. The business clears just 3 percent profit margins and a 4 percent return on equity, numbers that already signal thin returns before any downturn hits.
Our numbers put fair value at 11.16 dollars against the current 12.97 dollars, so the shares trade above what the cash flows justify. A 14.4 times forward multiple looks modest until you remember this is a cyclical industry where peak earnings often coincide with the lowest multiples. Narrow moat, modest revenue growth and an ethical pass do not change the fact that the valuation already prices in recovery without enough margin of safety.
Analyst targets sit higher, yet those forecasts tend to extrapolate the good years. The real risk is that construction spending slows, margins compress further and the low multiple proves to be a trap rather than a bargain. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: its business and earnings are exposed to Mexico and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CX trades on the NYSE (the company is based in Mexico). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-04Accumulation$10.59+3.8%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 72%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (15 analysts) rates it buy, with a mean price target of $14. Insiders have been net buyers over the past quarter.
2026-10-28Accumulation$10.20+1.4%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 72%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (15 analysts) rates it buy, with a mean price target of $14. Insiders have been net buyers over the past quarter.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 5.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 72%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (15 analysts) rates it buy, with a mean price target of $14. Insiders have been net buyers over the past quarter.
2026-10-14Markdown$9.56-4.6%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 4.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 17% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 72%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (15 analysts) rates it buy, with a mean price target of $14. Insiders have been net buyers over the past quarter.
2026-10-02Markdown$10.02-9.6%Entry 6
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 9.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 17% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 72%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (15 analysts) rates it buy, with a mean price target of $14. Insiders have been net buyers over the past quarter.
2026-08-26Markdown · changed$11.08-14.6%Entry 5
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 14.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 17% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 72%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (15 analysts) rates it buy, with a mean price target of $14.
2026-07-26Markup$12.97-0.1%Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 17% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 72%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (15 analysts) rates it buy, with a mean price target of $14.
2026-07-18Markup$12.98+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 17% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 72%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (15 analysts) rates it buy, with a mean price target of $14.
2026-07-03Markup$12.98+0.0%Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markup$12.98Entry 1
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
